+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Potential Analysis of Human DNA Vaccines Market by Forecast Scenario Analysis - Global Opportunity Analysis and Industry Forecast, 2020-2030

  • ID: 4612768
  • Report
  • June 2017
  • Region: Global
  • 120 pages
  • Allied Analytics LLP
1 of 4
DNA vaccines are third-generation vaccines and consist of a small circular piece (DNA sequence) of bacterial DNA, which is used for the immunization. DNA vaccine is used for protecting humans against disease by injecting them with genetically engineered DNA to produce an immunological response by activating the host against the gene delivered. DNA vaccines are advantageous over traditional vaccines as the expression of native virus with the antigen is more similar as compared to conventional vaccines, and several antigen or proteins can be delivered in a single dose. In addition, large-scale production can be carried out at a cost lower than conventional method of vaccines. The global potential analysis of DNA vaccines market is expected to account $3,762 million in 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030.

The global potential analysis of human DNA vaccine market is segmented based on forecast scenario analysis and region. Based on forecast scenario analysis, it is divided into rapid growth scenario, moderate growth scenario, and low growth scenario. The market analysis based on region includes North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS

In-depth study of the global potential market for DNA vaccines is conducted based on the current disease prevalence, target population, and pricing for generating market size and forecast from 2020 to 2030.

Potential analysis of opportunities is evaluated to understand different aspects of DNA vaccines that are currently under various phases of clinical trials along with the variants that would gain prominence in the future.

Vaccine pipeline products against DNA, which are under various clinical stages, are covered.

Key market players are profiled and their strategies are analyzed thoroughly to understand various technologies adopted to manufacture DNA vaccines.

KEY MARKET SEGMENTS

By Forecast Scenario Analysis

Rapid Growth Scenario

Moderate Growth Scenario

Low Growth Scenario

By Region

North America

Europe

Asia-Pacific

LAMEA

KEY PLAYERS

Inovio Pharmaceuticals, Inc.

GeneOne Life Science Inc.

MedImmune

Immunomic Therapeutics, Inc.

Astellas Pharma, Inc.

Pharos Biologicals

Sanofi S.A.

F. Hoffmann-La Roche AG

CureVac

Boehringer Ingelheim GmbH
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.3. TOP INVESTMENT POCKETS
3.4. HUMAN DNA VACCINES-KEY FACTS
3.5. REGULATION OF VACCINES BY FDA
3.6. CLINICAL TRIALS
3.7. PRICING FOR TOP GLOBAL VACCINE PRODUCTS
3.8. MARKET OPPORTUNITIES

CHAPTER 4 FORECAST SCENARIO ANALYSIS OF HUMAN DNA VACCINES MARKET
4.1. OVERVIEW
4.1.1. Market size & forecast
4.1.1.1. Rapid growth scenario
4.1.1.2. Moderate growth scenario
4.1.1.3. Low growth scenario

CHAPTER 5 GLOBAL POTENTIAL ANALYSIS OF HUMAN DNA VACCINES MARKET, BY GEOGRAPHY
5.1. OVERVIEW
5.2. NORTH AMERICA
5.2.1. Key opportunities
5.2.2. Market size & forecast
5.3. EUROPE
5.3.1. Key opportunities
5.3.2. Market size & forecast
5.4. ASIA-PACIFIC
5.4.1. Key opportunities
5.4.2. Market size & forecast
5.5. LAMEA
5.5.1. Key opportunities
5.5.2. Market size & forecast

CHAPTER 6 COMPANY PROFILES
6.1. INOVIO PHARMACEUTICALS, INC.
6.1.1. Overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Business performance
6.1.5. Product pipeline
6.1.6. Research funding
6.1.7. Key strategic developments
6.2. GENEONE LIFE SCIENCE INC.
6.2.1. Overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Business performance
6.2.5. Product pipeline
6.2.6. Research funding
6.2.7. Key strategic developments
6.3. MEDIMMUNE
6.3.1. Overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Business performance
6.3.5. Product pipeline
6.3.6. Research funding
6.3.7. Key strategic developments
6.4. IMMUNOMIC THERAPEUTICS, INC.
6.4.1. Overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Business performance
6.4.5. Product pipeline
6.4.6. Research funding
6.4.7. Strategic moves and developments
6.5. ASTELLAS PHARMA, INC.
6.5.1. Overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Business performance
6.5.5. Product pipeline
6.5.6. Research fuding
6.5.7. Strategic moves and developments
6.6. PHAROS BIOLOGICALS
6.6.1. Overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Business performance
6.6.5. Product pipeline
6.6.6. Research funding
6.6.7. Strategic moves and developments
6.7. SANOFI S.A.
6.7.1. Overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Business performance
6.7.5. Product pipeline
6.7.6. Research funding
6.7.7. Strategic moves and developments
6.8. F. HOFFMANN-LA ROCHE AG
6.8.1. Overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Business performance
6.8.5. Product pipeline
6.8.6. Research funding
6.8.7. Strategic moves and developments
6.9. CUREVAC
6.9.1. Overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Business performance
6.9.5. Product pipeline
6.9.6. Research fuding
6.9.7. Strategic moves and developments
6.10. BOEHRINGER INGELHEIM GMBH
6.10.1. Overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Business performance
6.10.5. Product pipeline
6.10.6. Research funding
6.10.7. Strategic moves and developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
According to a new report titled, Potential Analysis of Human DNA Vaccines Market by Forecast Scerio: Global Opportunity Alysis and Industry Forecast, 2020-2030, the global potential alysis of human D vaccines market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.

Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas D vaccines consist of the D sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditiol approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture. In addition, D vaccines are temperature stable, leading to easier storage and transport. D vaccition may provide an important tool for stimulating an immune response in HBV, HCV, and HIV patients, owing to their therapeutic potential for ongoing chronic viral infection. For instance, Inovios INO-3112 is in phase II clinical trial, and can be used to treat cervical cancer caused by HPV. This immunotherapy ebles the body to produce E6 and E7 antigens to induce a stronger targeted immune response against HPV-associated diseases, such as cervical cancer.

Key findings of the Potential Alysis of Human D Vaccines Market:

North America is expected to domite the market in 2020, and is projected to grow at the highest CAGR during the forecast period.
Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.
The major players profiled in the global potential alysis of human D vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.
Note: Product cover images may vary from those shown
5 of 4

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll